Efficacy End Points
SECONDARY, HOFH
The primary end point was the percentage change in LDL-C level from baseline to day 150 (part 1 of the study). Key secondary end points were the absolute change in LDL-C level from baseline to day 150 and the percentage change in apoB (apolipoprotein B100), non–high-density lipoprotein cholesterol (non-HDL-C), and total cholesterol levels from baseline to day 150. Other secondary end points were the absolute and percentage changes in LDL-C, PCSK9, apoB, non–HDL-C, lipoprotein(a), and total cholesterol levels from baseline to day 720.An exploratory end point evaluated the response of LDL-C level reduction by underlying causal sequence variations of HoFH at day 150. A post hoc analysis was conducted to evaluate the placebo-corrected percentage change in LDL-C level from baseline, excluding patients with apheresis and double-null alleles for 